Pharmaceutical companies have predominantly concentrated on developing innovative therapies in developed countries, where the cost of development is relatively high, resulting in higher price points that are often unaffordable in many regions globally. This creates a significant delay in access to these novel branded therapies for patients, particularly where insurance coverage is limited. Despite the increasing emphasis on biotech products across various therapy areas, many patients still lack access to these targeted therapies even after generic versions become available, as biosimilars also remain expensive in out-of-pocket settings.
There is a significant need to develop affordable solutions to ensure broader access to innovative pharmacotherapies. Our approach involves developing cost-effective, innovative therapies that serve as alternatives to expensive treatments by prioritizing low-risk, proven pathways and focusing on cost-effective development strategies.